INCOME TAXES	3 Months Ended
Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three months ended March 31, 2015 and 2014, the effective tax rate (“ETR”) was 23.7% and 25.5%, respectively. The ETR decrease was primarily due to a favorable change in the geographic earnings mix, partially offset by accrued U.S. and foreign taxes on dividends to be paid by foreign subsidiaries and the accrual related to the China investigation which may be partially or wholly non-deductible for tax purposes, depending upon the final resolution of such matter. See Note 19. Contingencies for further discussion regarding the accrual related to the China investigation. The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of March 31, 2015 and December 31, 2014, was $155.7 million and $146.8 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. The Company is currently under examination by taxing authorities in various jurisdictions in which it operates, including the United States. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of the reserve for uncertain tax positions. Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has a receivable from BMS for uncertain tax positions, including penalties and interest, of $9.8 million and $9.7 million as of March 31, 2015 and December 31, 2014, respectively.

INCOME TAXES

3 Months Ended

Mar. 31, 2015

For the three months ended March 31, 2015 and 2014, the effective tax rate (“ETR”) was 23.7% and 25.5%, respectively. The ETR decrease was primarily due to a favorable change in the geographic earnings mix, partially offset by accrued U.S. and foreign taxes on dividends to be paid by foreign subsidiaries and the accrual related to the China investigation which may be partially or wholly non-deductible for tax purposes, depending upon the final resolution of such matter. See Note 19. Contingencies for further discussion regarding the accrual related to the China investigation.

The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of March 31, 2015 and December 31, 2014, was $155.7 million and $146.8 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. The Company is currently under examination by taxing authorities in various jurisdictions in which it operates, including the United States. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of the reserve for uncertain tax positions.

Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has a receivable from BMS for uncertain tax positions, including penalties and interest, of $9.8 million and $9.7 million as of March 31, 2015 and December 31, 2014, respectively.